The PREPARE Study (V1) 
Page [ADDRESS_1020278] Su rgery 
 
The PREPARE Study 
 
  
Compound: DEXTENZA (dexamethasone 
ophthalmic insert) 0.4 mg, for 
intracanalicular use 
  
Study Name: [CONTACT_746052] O ptometrist Inse rtion of 
Dextenza Prior to C ataract Su rgery 
 
The Prepare Study 
 
  
Clinical Phase: Investigator-Initiated Clinical Trial 
  
Date of Issue: 9/24/2020 
  
Primary Investigator: Mitch Ibach, OD 
  
Sub Investigator: Justin Schweitzer, OD 
John Berdahl, MD 
Doug Wallin, OD 
Keith Rasmussen, OD 
Vance Thompson, MD 
Larae Zimprich, OD 
Jason Schmit, OD 
Daniel Terveen, MD 
 
Site Name & Location: Vance Thompson Vision Center 
[ADDRESS_1020279] 
Sioux Falls, South Dakota 
[ZIP_CODE] 
  
  
The PREPARE Study (V1)  
February, 2021  Page 21 
 CONFIDENTIAL CLINICAL STUDY PROTOCOL SYNOPSIS 
TITLE The PREPARE Study 
SITE LOCATION(S) 
 Vance Thompson Vision Center 
[ADDRESS_1020280] 
Sioux Falls, South Dakota 
[ZIP_CODE]  
PRINCIPAL 
INVESTIGATOR [INVESTIGATOR_746030], OD 
 
OBJECTIVE(S) To evaluate the clinical outcomes with optometrist 
pre-surgical insertion of DEXTENZA in the clinical 
office setting in patients undergoing same-day 
cataract surgery compared to standard of care 
steroid therapy. 
STUDY DESIGN Prospective Open-label Interventional Study 
STUDY DURATION 2-3 months from start-up 
ESTIMATED STUDY 
COMPLETION DATE Insert date of study completion  
POPULATION  
Sample Size: N=60 (30 patients, 60 eyes) 
Target Population: Patients planning to undergo sequential bilateral 
cataract surgery. 
TREATMENT(S)  
  
Study Drug 
  
 
Dose/Route/Schedule: DEXTENZA (dexamethasone ophthalmic insert) 0.[ADDRESS_1020281] eye 
randomized to either the Control Group or the 
Experimental Group. The second eye will be selected 
for the opposite group. All eyes will receive 
intracameral 
dexamethasone+moxifloxacin+ketorolac (DMK) at 
the time of surgery. All eyes will be placed on topi[INVESTIGATOR_15877] (Vigamox 0.5%) QID for one week and 
topi[INVESTIGATOR_609008] ((Prolensa (Bromfenac 0.07%)) QD for 
one month.  
 
Experimental Group (Treatment A): [ADDRESS_1020282] 
surgery. 
 
Control Group (Treatment B): 30 eyes will receive 
The PREPARE Study (V1)  
February, 2021  Page 22 
 CONFIDENTIAL topi[INVESTIGATOR_416379] 1% QID for one week, TID 
for one week, BID for one week, QD for one week. 
 
ENDPOINT(S)  
Primary: To determine the effect of dexamethasone 
intracanalicular insert through Week 4 as measured 
by: 
x Mean anterior chamber cell/flare score as 
measured by [CONTACT_746039] 0 to 4 + 
(SUN Working Group Grading Scheme) at 
post-op Day 1, Day 7, and Week 4.  
x Mean pain score as measured by [CONTACT_746040] 0-[ADDRESS_1020283]-op Day 1, Day 7, and Week 4. 
To determine patient preference through Week 4 as 
measured by: 
x Adapted COMTOL Questionnaire at Week 4.  
Secondary: To determine the effect of dexamethasone 
intracanalicular insert through Week 4 or 12: 
x Incidence of increased intraocular pressure 
(IOP) >10mmHg above baseline as measured 
by [CONTACT_746041]-
op Day 1, Day 7, and Week 4. 
x Incidence of Cystoid Macular Edema (CME) as 
measured by [CONTACT_7349] 
(OCT) at post-op Week 4. 
To determine physician ease of insertion following 
dexamethasone intracanalicular insert placement 
prior to same-day surgery as measured by: 
x Physician Ease of Use Survey following 
dexamethasone intracanalicular placement on 
Surgical Visit Day 0.  
To determine eye drop therapy burden on the patient 
through Week 4 as measured by: 
x Eye Drop Burden Questionnaire at post-op 
Day 7 and Week 4.  
 
 
The PREPARE Study (V1)  
February, [ADDRESS_1020284] OF TABLES 
Table 1 Schedule of Events ............................. Error! Bookmark not defined. 
  
The PREPARE Study (V1)  
February, 2021  Page 24 
 CONFIDENTIAL Introduction and Rationale 
Introduction 
 Dextenza (dexamethasone 0.4mg ophthalmic insert) is a steroid eluting 
intracanalicular plug approved on-label for the treatment of pain and postope rative 
inflammation in patients who‚Äôve undergone ocular surgery. Utilizing Dextenza, in plac e 
of ophthalmic steroid drops, will provide patients with a lessened number of  post-
operative drops which decreases both contamination possibilities and impr oper drug 
installation. Dextenza‚Äôs hydrogel technology is proposed to offer patients a gradua l 
sustained delivery of steroid to the ocular surface which may decrease subjecti ve post-
operative pain.  
 
 Post-operative drop regimens frequently induce both concerns and questions for 
patients undergoing ocular surgery. Poor compliance with postoperative medications  can 
lead to unexpected and or unsatisfactory outcomes. In post-operative catarac t surgery 
patients, un-treated or non-resolving inflammation can lead to pain, anterior cham ber 
inflammation, and potentially cystoid macular edema (CME). Lessening the risk of  these 
adverse events due to drop complications is a key benefit of Dextenza. There may b e 
future possibilities to combine intracameral medication combinations (a ntibiotic, steroid, 
NSAID) plus Dextenza to further reduce the patient post-operative drop burden.  
 
 On introduction to the market, Dextenza was most commonly inserted in the 
operating room (OR) pre-cataract surgery, but other instillation protoco ls will increase 
practitioner adoption and patient access. Increasing optometrist adm inistration in clinic 
allows for another route for insurance reimbursement while freeing up ophthalm ologists 
in the OR.  
 
 
Rationale 
 DEXTENZA (dexamethasone 0.4mg ophthalmic insert) has increasing research  
and evidence for post-cataract surgery patients, but a gap remains in bes t practices for 
instillation timing and protocols. In clinic insertion provides another route for  device 
administration which can help foster additional reimbursement codes.  
 
  Dextenza‚Äôs ability to treat post-operative inflammation while also increa sing 
remaining tear volume by [CONTACT_746042]-operative drop inconvenience. The studied p atient 
population is having their initial cataract evaluation and surgery on the same day, 
decreasing patient inconvenience, adding Dextenza is another arrow in the quiver.  
 
 
Rationale for Study Design 
 This prospective contralateral eye study will compare the outcomes of [ADDRESS_1020285] surgery. All eyes will receive intracameral DMK at the  conclusion of 
surgery. All eyes will be treated with Vigamox 0.5% QID for 1 week and Prolensa 
The PREPARE Study (V1)  
February, 2021  Page 25 
 CONFIDENTIAL (bromfenac 0.07%) QD for [ADDRESS_1020286] of topi[INVESTIGATOR_746031] 1% QID [ADDRESS_1020287] of dexamethasone intracanalicular insert  through 
Week 4 as measured by: 
x Mean anterior chamber cell score as measured by [CONTACT_746043] 0 to 4 + ( SUN Working 
Group Grading Scheme) at post-op Day 1, Day 7, and Week 4.   
x Mean pain score as measured by [CONTACT_746044] 0-[ADDRESS_1020288]-op Day 1, Day 7, and Week 4.  
To determine patient preference through Week 4 as measured by: 
x Adapted COMTOL Questionnaire at Week 4. 
 
Secondary Objectives 
To determine the effect of dexamethasone intracanalicular insert  through 
Week 4 or 12: 
x Mean anterior chamber flare score as measured by [CONTACT_746043] 0 to 4 + ( SUN Working 
Group Grading Scheme) at post-op Day 1, Day 7, and Week 4.   
x Incidence of increased intraocular pressure (IOP) >10mmHg above 
baseline as measured by [CONTACT_746041]-op 
Day 1, Day 7, and Week 4. 
x Incidence of Cystoid Macular Edema (CME) as measured by [CONTACT_746045] (OCT) at post-op Week 4. 
To determine physician ease of insertion following dexamethaso ne 
intracanalicular insert placement prior to same-day sur gery as measured by: 
x Physician Ease of Use Survey following dexamethasone 
intracanalicular placement on Surgical Visit Day 0.  
To determine eye drop therapy burden on the patient through Week 4  as 
measured by: 
x Eye Drop Burden Questionnaire at post-op Day 7 and Week 4.  
 
The PREPARE Study (V1)  
February, [ADDRESS_1020289] surgery. 
 
Inclusion Criteria 
A patient‚Äôs study eye must meet the following criteria to be el igible for 
inclusion in the study: 
x Patients [ADDRESS_1020290] surgery.  
x Willing and able to comply with clinic visits and stu dy related 
procedures 
x Willing and able to sign the informed consent form 
 
 
Exclusion Criteria 
A patient who meets any of the following criteria will be exc luded from the 
study: 
x Patients under the age of 18. 
x Patients who are pregnant (must be ruled out in women of ch ild-
bearing age with pregnancy test). 
x Active infectious ocular or systemic disease. 
x Patients with active infectious ocular or extraocular diseas e. 
x Patients actively treated with local or systemic immunos uppression 
including systemic corticosteroids. 
x Patients with known hypersensitivity to Dexamethasone. 
x Patients with severe disease that warrants critical atten tion, deemed 
unsafe for the study by [CONTACT_093]. 
x Patients with proliferative diabetic retinopathy or uncontrol led 
diabetes as deemed by [CONTACT_1629] A1C > 10.0. 
x Patients with a history of ocular inflammation or macular  edema. 
x Patients with a pre-existing epi[INVESTIGATOR_43691] (ERM) 
x Patients with allergy or inability to receive intracamer al antibiotic. 
x Patients on systemic non-steroidal anti-inflammatory drugs  (NSAID) 
greater than 1,200 mg/day 
The PREPARE Study (V1)  
February, 2021  Page 27 
 CONFIDENTIAL x Patients with a corticosteroid implant (i.e. Ozurdex).  
 
Treatment Logistics and Accountability 
Packaging, Labeling, and Storage 
Intracanalicular dexamethasone insert must be stored in a s ecure area 
accessible only to the Investigator and their designee(s) and refrigerated and 
stored between [ADDRESS_1020291]-surgical inflammation an d pain associated 
with ocular surgery. Dexamethasone is an anti-inflammatory  9-fluoro-
glucocorticoid (also termed a glucocorticoid agonist) and is  the active 
ingredient found in MAXIDEX ¬Æ 0.1% (dexamethasone ophthalmic 
su VSHQVLRQZKLFKFRQWDLQVDSSUR[LPDWHO\«çJRIGH[DPHWK DVRQHSHUGURS  
Study inserts will be supplied by [CONTACT_431374] a  sealed foil pouch 
containing one intracanalicular dexamethasone insert in a f oam carrier. 
Study inserts will be shipped to the site via overnight shi ppi[INVESTIGATOR_455307] a temperature of 2¬∞ to 8¬∞ C. The Investig ator, or an 
approved representative (e.g. pharmacist), will ensure tha t all study drug 
inserts are stored in a secured area, under recommended storage conditions 
and in accordance with applicable regulatory requirements. The shippi[INVESTIGATOR_455308] a refriger ator intended 
for investigational products at a temperature of 2¬∞ to 8¬∞C.  
 
When the insert is removed from the refrigerator, it should be visually 
inspected. Exposure of the insert to temperatures outside these l imits it not 
recommended. Records of actual storage conditions (i.e. temperat ure log) at 
the study site must be maintained; and must include a rec ord of the dates, 
when the refrigerator was checked, the initials of person check ing, and the 
temperature. 
 
Supply and Disposition of Treatments 
Study insert will be shipped at a temperature of 2¬∞ to 8¬∞C to the investigator 
as needed during the study.  
 
Treatment Accountability 
All study insert accountability records will be kept curr ent. 
 
The investigator will account for all opened and unopened pack aging of study 
inserts.  These records will contain the dates, quantity, a nd study medication 
x Inserted in each patient, 
x disposed of at the site or returned to Ocular Therapeutix 
The PREPARE Study (V1)  
February, [ADDRESS_1020292] treatments administered for other c onditions. 
 
Study Schedule of Events and Visit Descriptions 
Schedule of Events 
Study assessments and procedures are presented by [CONTACT_523063] 1 below. 
The PREPARE Study (V1)  
February, 2021  Page 29 
 CONFIDENTIAL Table 1 Schedule of Events 
 
 Study Procedure  
Screening/ 
Baseline 
 
 
 First 
Eye 
Surgical 
Visit 
Day [ADDRESS_1020293]-op  
Both 
Eyes 
 
 Early 
Termination 
Visit V ISIT 1 V ISIT 2 VISIT 3 VISIT 4 VISIT 5 VISIT 
6 VISIT 7 VISIT 8  
Windows for Visits 
(Day -30 to 0)     +/- [ADDRESS_1020294] 
eye sx +/- [ADDRESS_1020295] eye 
sx +/- [ADDRESS_1020296] eye 
sx  
Inclusion/Exclusion X         
Informed Consent X         
Demographics X         
Medical History and Concurrent Illnesses X X X X X X X X  
Concomitant Medications X X X X X X X X  
Uncorrected Distance VA  X  X  X X X X  
MRX X     X X X  
BCVA (ETDRS at 4m) X     X X X  
Ophthalmic Examination (dilated fundus 
exam) X      X   
Slit lamp exam X  X  X X X X  
Grade cataract density (scale 1 to 4)  X  X      
OCT  X      X   
Intraocular Pressure X  X  X X X X  
Indicate the incision type, location, and 
size (mm) 
  X  X     
 
Type of IOL (e.g. monofocal, toric, 
multifocal, etc.) and lens power 
  X  X     
 
Record any surgical complications 
  X  X      
Subject reported AEs prior to or after 
surgery 
  X X X X X X X 
 
Intracanalicular dexamethasone insert 
(*if randomized to Dextenza arm) 
  X  X     
 
Intracameral injection of 
NSAID+antibiotic+steroid combo  X  X      
Physician Ease of Use Survey  X  X      
Eye Drop Burden Questionnaire      X X   
Adapted COMTOL Questionnaire       X   
Ocular Pain Assessment X  X  X X X X  
Anterior chamber cell count X  X  X X X X  
Anterior chamber cell flare X  X  X X X X  
Insert Visualization 
 X X X X X X X 
 
Prescribe post-operative topi[INVESTIGATOR_746032] (*specific to each study group)  X  X      
The PREPARE Study (V1)  
February, 2021  Page 30 
 CONFIDENTIAL 5.2    Study Visit Descriptions 
5.2.1 Study Procedures 
Screening/Baseline 
After the patient has provided informed consent, the followin g information 
will be collected (if the data was collected within [ADDRESS_1020297] previous exam) : 
x Inclusion/exclusion 
x Demographics 
x Medical history and concurrent illnesses 
x Concomitant medications 
x Distance VA 
x MRX 
x BCVA 
x Ophthalmic Examination (dilated fundus exam) 
x Slit lamp Exam 
x OCT 
x IOP 
x Ocular Pain Assessment 
x Anterior Chamber Cell Count 
x Anterior Chamber Cell Flare 
 
Surgical Visit Day [ADDRESS_1020298] Density (scale 1 to 4) 
x Indicate incision type, location, and size 
x Type of IOL and lens power 
x Record any surgical complications 
x Subject reported AEs prior to or after surgery 
x Insert intracanalicular dexamethasone insert (*if randomized  to 
Dextenza arm) 
x Physician Ease of Use Survey 
x Intracameral injection of NSAID+abx+steroid combo 
x Insert visualization 
x Prescribe post-operative regimen (*specific to each eye) 
 
Day [ADDRESS_1020299] Eye (To be completed prior to 2nd eye sx) 
x Medical history and concurrent illnesses 
x Concomitant medications 
x Distance VA 
x Slit lamp Exam 
x IOP 
x Subject reported AEs prior to or after surgery 
x Ocular Pain Assessment 
The PREPARE Study (V1)  
February, 2021  Page 31 
 CONFIDENTIAL x Anterior Chamber Cell Count 
x Anterior Chamber Cell Flare 
x Insert visualization 
 
Surgical Visit Day 0 Second Eye (To be completed one day after first eye sx) 
x Medical history and concurrent illnesses 
x Concomitant medications 
x Grade Cataract Density (scale 1 to 4) 
x Indicate incision type, location, and size 
x Type of IOL and lens power 
x Record any surgical complications 
x Subject reported AEs prior to or after surgery 
x Insert intracanalicular dexamethasone insert (*if randomiz ed to 
Dextenza arm) 
x Physician Ease of Use Survey 
x Intracameral injection of NSAID+abx+steroid combo 
x Insert visualization 
x Prescribe post-operative regimen (*specific to each eye) 
 
 
Day [ADDRESS_1020300] reported AEs prior to or after surgery 
x Ocular Pain Assessment 
x Anterior Chamber Cell Count 
x Anterior Chamber Cell Flare 
x Insert visualization 
 
Day 7 (+/- [ADDRESS_1020301] eye sx) 
x Medical history and concurrent illnesses 
x Concomitant medications 
x Distance VA 
x MRX 
x BCVA 
x Slit lamp Exam 
x IOP 
x Subject reported AEs prior to or after surgery 
x Eye Drop Burden Questionnaire 
x Ocular Pain Assessment 
x Anterior Chamber Cell Count 
The PREPARE Study (V1)  
February, 2021  Page 32 
 CONFIDENTIAL x Anterior Chamber Cell Flare 
x Insert visualization 
 
Day 28-35 (+/- [ADDRESS_1020302] eye sx) 
x Medical history and concurrent illnesses 
x Concomitant medications 
x Distance VA 
x MRX 
x BCVA 
x Ophthalmic examination (dilated fundus exam) 
x Slit lamp Exam 
x OCT 
x IOP 
x Subject reported AEs prior to or after surgery 
x Eye Drop Burden Questionnaire 
x Adapted COMTOL Questionnaire 
x Ocular Pain Assessment 
x Anterior Chamber Cell Count 
x Anterior Chamber Cell Flare 
x Insert visualization 
 
Month 3 (+/- [ADDRESS_1020303] eye sx) 
x Medical history and concurrent illnesses 
x Concomitant medications 
x Distance VA 
x BCVA 
x Slit lamp Exam 
x IOP 
x Subject reported AEs prior to or after surgery 
x Ocular Pain Assessment 
x Anterior Chamber Cell Count 
x Anterior Chamber Cell Flare 
x Insert visualization 
 
 
Unscheduled Visits 
All attempts should be made to keep patients on the study sch edule.  
Unscheduled visits may be necessary to repeat testing followi ng abnormal 
laboratory results, for follow-up of AEs, or for any other reas on, as 
warranted. 
 
Adverse Event Information Collection 
The investigator (or designee) will record all AEs that occur  during the study  
The definition of an AE and SAE, and information on the deter mination of 
The PREPARE Study (V1)  
February, 2021  Page 33 
 CONFIDENTIAL severity and relationship to treatment are provided in Section 6. 
 
Rescue Criteria 
x Patients should be rescued at any time at the discretion of the 
investigator. 
x The following rescue criteria are to be applied by [CONTACT_31691]: 
o ¬ï*UDGH 3 anterior chamber cells 
o Ocular pain score of > 5 due to ocular inflammation 
x Patients requiring rescue therapy will be prescribed: topic al steroid and 
topi[INVESTIGATOR_746033]. 
If a patient requires rescue therapy in the eye containing the dexamethasone 
insert, the insert will not be removed, and subjects will b e followed for safety. 
 
Safety Definitions, Reporting, and Monitoring 
Definitions 
Adverse Event 
An AE is any untoward medical occurrence in a patient a dministered a study 
drug which may or may not have a causal relationship wit h the study drug.  
Therefore, an AE is any unfavorable and unintended sign (i ncluding 
abnormal laboratory finding), symptom, or disease which is  temporally 
associated with the use of a study drug, whether or not con sidered related to 
the study drug.   
 
An AE also includes any worsening (i.e. any clinically s ignificant change in 
frequency and/or intensity) of a pre-existing condition tha t is temporally 
associated with the use of the study drug. 
 
Serious Adverse Event 
A SAE is any untoward medical occurrence that at any do se: 
x Results in d eath ‚Äì includes all deaths, even those that appear to be 
completely unrelated to study drug (e.g. a car accident in which a patient 
is a passenger). 
x Is life-threatening ‚Äì in the view of the investigator, the patient is at 
immediate risk of death at the time of the event.  This does n ot include an 
AE that had it occurred in a more severe form, might have caused death. 
x Requires in-patient h ospi[INVESTIGATOR_6929].  In-patient hospi[INVESTIGATOR_2140] a s admission to a 
hospi[INVESTIGATOR_28682] 24 hours.  Prolon gation of 
existing hospi[INVESTIGATOR_31561] a hospi[INVESTIGATOR_746034] (V1)  
February, 2021  Page 34 
 CONFIDENTIAL was originally anticipated for the event, or is prolonged due to the 
development of a new AE as determined by [CONTACT_746046]. 
x Results in persistent or significant d isability/incapacity (substantial 
disruption of one‚Äôs ability to conduct normal life function s). 
x Is a c ongenital anomaly/birth defect 
x Is an i mportant medical event ‚Äì Important medical events may not be 
immediately life-threatening or result in death or hospi[INVESTIGATOR_1916], but may 
jeopardize the patient or may require intervention to prevent 1 of  the 
other serious outcomes listed above (e.g., intensive treatment i n an 
emergency room or at home for allergic bronchospasm; blood dyscr asias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; or developm ent of drug 
dependency or drug abuse).  Any malignancy (other than bas al cell skin 
cancers) would be considered a medically important event. 
 
Recording and Reporting Adverse Events 
All AEs and SAEs will be recorded only if they are medicall y relevant. 
 
All SAEs, regardless of assessment of causal relationship t o study insert will 
be reported to Ocular Therapeutix. 
To report an SAE, Ocular Therapeutix will be contact[CONTACT_6811] t he 
following: 
[EMAIL_8231] 
SAE hotline: [PHONE_9545] 
 
The investigator will promptly report to the IRB all unant icipated problems 
involving risks to patients.  This includes death from an y cause and all SAEs 
related to the use of the study insert.  All SAEs will be rep orted to the IRB, 
regardless of assessed causality. 
 
Study Variables 
Demographic and Baseline Characteristics 
Baseline characteristics will include standard demography  (e.g. age, race, 
weight, height, etc.), disease characteristics includin g medical history, and 
medication history for each patient. 
 
Ethical and Regulatory Considerations 
Good Clinical Practice Statement 
It is the responsibility of the investigator(s) to ensure tha t this clinical study 
will be conducted in accordance with the ethical princip les that have their 
origin in the Declaration of Helsinki, and that are consist ent with the ICH 
guidelines for Good Clinical Practice (GCP) and applicabl e regulatory 
requirements. 
 
The PREPARE Study (V1)  
February, [ADDRESS_1020304] the right to review and com ment on the 
informed consent form. 
 
It is the responsibility of the investigator or designee (if a cceptable by [CONTACT_13125]) to obtain written informed consent from each pati ent prior to 
his/her participation in the study and after the aims, m ethods, objectives, and 
potential hazards of the study have been explained to the pati ent in language 
that he/she can understand.  The ICF will be signed and d ated by [CONTACT_746047].   
 
Patients who can write but cannot read will have the ICF read to them before 
signing and dating the ICF. 
Patients who can understand but who can neither write nor read will have 
the ICF read to them in presence of an impartial witness, w ho will sign and 
date the ICF to confirm that informed consent was given. 
 
The original ICF will be retained by [CONTACT_746048]‚Äôs 
study record, and a copy of the signed ICF will be given t o the patient. 
 
If new safety information results in significant changes in the risk/benefit 
assessment, the ICF will be reviewed and updated appropri ately.  All study 
patients will be informed of the new information and provide t heir written 
consent if they wish to continue in the study.  The original  signed revised ICF 
will be maintained in the patient‚Äôs study record and a c opy will be given to 
the patient. 
 
Patient Confidentiality and Data Protection 
The investigator will take all appropriate measures to ensure that the 
anonymity of each study patient will be maintained.   
 
The patient‚Äôs and investigator‚Äôs personal data will be tr eated in compliance 
with all applicable laws and regulations.   
 
Institutional Review Board  
An appropriately constituted IRB, as described in ICH Gui delines for GCP, 
will review and approve:  
x The protocol, ICF, and any other materials to be provided to th e 
patients (e.g. advertising) before any patient may be enrolled  in the study  
x Any amendment or modification to the study protocol or ICF befo re 
implementation, unless the change is necessary to eliminate an 
The PREPARE Study (V1)  
February, [ADDRESS_1020305] to the patients, in which case the IRB wi ll be informed 
as soon as possible  
 
Ongoing studies will be reviewed by [CONTACT_1201]/EC on an annua l basis or at 
intervals appropriate to the degree of risk.  
 
In addition, the IRB will be informed of any event likely to affect the safety of 
patients or the continued conduct of the clinical study. 
 
A copy of the IRB approval letter will be sent to Ocular T herapeutix prior to 
shipment of drug insert supplies to the investigator.  The approval letter will 
include the study title, the documents reviewed, and the dat e of the review. 
 
Records of the IRB review and approval of all study documen ts (including 
approval of ongoing studies) will be kept on file by [CONTACT_74169]. 
 
The PREPARE Study (V1)  
February, 2021  Page 37 
 CONFIDENTIAL  
APPENDICES 
 
Protocol Appendix A: Ease of use Survey 
Protocol Appendix B: Eye Drop Burden Questionnaire 
Protocol Appendix C: Adapted COMTOL 
 
 
REFERENCES 
 
 
1.  DEXTENZA  [PACKAGE INSERT ].  BEDFORD , MA:  OCULAR THERAPEUTIX , 
INC ; 2019.   
 
2.  Walters TR, Bafna S, Vold S, et al. Efficacy and Safety of Sustained 
Release Dexamethasone for the Treatment of Ocular Pain and 
Inflammation after Cataract Surgery: Results from Two Phas e 3 
Studies . J Clin Exp Ophthalmol . 2016;7(4):1-11.  
 
3.  Tyson SL, Bafna S, Gira JP, et al. Multicenter randomized p hase [ADDRESS_1020306] surgery. 
[published correction appears in J Cataract Refract Surg . 
2019;45(6):895]. J Cataract Refract Surg . 2019;45(2):204-212. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PREPARE Study (V1)  
February, 2021  Page 38 
 CONFIDENTIAL  
Protocol Appendix A: Ease of Use Survey 
 
The investigator will grade the level of ease of in sertion of the intracanalicular 
insert on a [ADDRESS_1020307]  
The PREPARE Study (V1)  
February, 2021  Page 39 
 CONFIDENTIAL Protocol Appendix B: Eye Drop Burden Questionnaire  
 
  Never 
 
1 Rarely 
 
2 Sometimes 
 
3 Usually 
 
4 Always 
 
5 
1.   I forget to 
administer my eye 
drops.      
2.   It is difficult 
and/or frustrating 
to administer my 
eye drops.      
3.   My eye drops 
burn and/or sting 
when I administer 
them.      
4.   My eye drop 
treatment 
interferes with the 
daily activities of 
my life.      
5.   I forget to wash 
my hands prior to 
administering my 
eye drops.      
6.   I accidentally 
administer more 
and/or less than 
one eye drop to 
the eye.      
7.   The drops miss 
my eye when I 
administer them.      
8.    The bottle tip 
touches my eye 
when using my 
eye drops.      
  
Add up the numbers for each statement to calculate the total Eye Drop Burden 
Score. 
 
Total Eye Drop Burden Score = ___ 
 
Low Eye Drop Burden: 8-18 
Moderate Eye Drop Burden: 19-29 
High Eye Drop Burden: 30-40 
 
The PREPARE Study (V1)  
February, 2021  Page 40 
 CONFIDENTIAL Protocol Appendix C: Adapted COMTOL  
 
Comparison of Ophthalmic Medications for Tolerability (COMTOL) Questionnai re (adapted to 
compare physician & patient administered ‚Äòfewer-drops‚Äô regimen ( (Treatment A- Experimental 
Group)) to patient-only administered total topi[INVESTIGATOR_8588] ((Treatme nt B- Control Group)). 
 
Interviewer: Please read the following verbatim! 
 
Thank you for participating in our study. Your evaluation of the test ‚Äúfewer-drops‚Äù trea tment 
(Treatment A- Experimental Group) that the surgeon and you administered followi ng your 
surgery compared to the total eyedrops (Treatment B- Control Group) you administer ed 
following surgery is most valuable to us. We would greatly appreciate your assista nce by 
[CONTACT_746049]. All answers are c onfidential. 
 
Every patient received both treatment regimens. Every patient recei ved Treatment A in one eye 
and Treatment B in the opposite eye. For clarification, here are the definitions  of each treatment 
group: 
 
Treatment A (Experimental Group- fewer-drops, physician & patient a dministered):  
 
x Dextenza (steroid punctal plug/insert) + Vigamox drops 4x/da y for 1 st  week + Prolensa drops 
1x/day for one month 
 
Treatment B (Control Group- total topi[INVESTIGATOR_746035], patient-only admi nistered): 
 
x Prednisolone drops 4x/day for 1 st  week, 3x/day for 2 nd  week, 2x/day for 3 rd  week, 1x/day for 
4th  week + Vigamox drops 4x/day for 1 st  week + Prolensa drops 1x/day for one month 
 
 
1.  (Interviewer: Questions 1 and 2 are to be asked only at the Month 1 Visit). 
Now that you tried both test regimens, did you prefer the Treatment A  (fewer-drops, physician & 
patient administered) regimen or the Treatment B (total eyedrop  therapy, patient-only administered) 
regimen? 
 (Interviewer: Please check the appropriate response below).  
___________ Treatment A regimen (Experimental Group-fewer drops) 
___________ Treatment B regimen (Control Group-all drops) 
___________ Neither (Do not read) 
 
 
 
2.   Why did you prefer your selected treatment?  (Interviewer: Read response from Question 
1) 
 
 
 
 
The PREPARE Study (V1)  
February, 2021  Page 41 
 CONFIDENTIAL  
 
 
 
 
 
 
‚ÄòFewer-Drops‚Äô Physician/Patient-Administered Therapy (Treatm ent A): Patient Reported 
Outcomes 
 
3.  (Interviewer: Read the following).  I am going to read to you a list of various side effects 
that may occur in some patients who receive Treatment A regimen (‚Äòfewer-dr ops‚Äô 
physician & patient administered regimen) following ophthalmic surgery.  You may ha ve 
experienced none, some, or all these side effects during the past month. As I rea d the list, 
please tell me if you experienced that side effect. (Interviewer: Check affirmative 
responses on the far left column of the list below Question #4. Pl ace a check under the 
column marked ‚ÄúI did not have the symptom‚Äù below Question #4 for those symptom s 
not experienced by [CONTACT_102]. If patient experienced none of t hese side effects, please 
check "None of these symptoms" below and go to Question #6).  
 
4.  (Interviewer: Refer to Question #3 and read the following).  I am now going to read to 
you the side-effects you said you experienced in the last question.  For each side effe ct I 
mention, please tell me how frequently you experienced each side effect dur ing the past 
month. (interviewer- hand respondent Card "A" with frequency scales.)  That is, did 
you experience the side effect rarely, a few times, often, use ally, almost alwa ys, or 
always? (Interviewer:  Place check under appropriate column below for each c hecked 
side effect mentioned by [CONTACT_225129]).  
 
 
The PREPARE Study (V1)  
February, 2021  Page 42 
 CONFIDENTIAL  
 
 
5.  (Interviewer: Refer to Question #4 and read the following).  I am again going to repeat 
the side-effects you just mentioned. For each side effect I mention, please t ell me if you 
have been bothered by [CONTACT_13114]: not at all, a little, some, quite a bit, very much so, or extr emely 
so? (Interviewer: Place check under appropriate columns below)  
   I Did Not 
Have the 
Symptom 
 Rarely A Few 
Times Fairly 
Often Usually Almost 
Always Always 
__ Burning/stinging in 
eyes (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Redness in eyes (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Blurred vision (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Bitter taste (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Unusual taste (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Itchy eyes (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Discharge from eyes (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Swelling of eyelids (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Brow ache (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Dimming of vision    (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Difficulty in focusing 
from near to far (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Dry eyes (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Trouble reading (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Trouble seeing at 
night (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Tearing (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ None of these 
symptoms (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
The PREPARE Study (V1)  
February, [ADDRESS_1020308] month has your quality of life been interfered with by [CONTACT_746050]:  
not at all, a little, some, quite a bit, very much so, or extremely so? 
 
__ Not at all 
__ A little 
__ Some 
__ Quite a bit 
__ Very much so 
__ Extremely so 
 
 
 
 
 
 
 
 
 
 
7.  (Interviewer ).  I am now going to show you a list of activities you might do during a 
typi[INVESTIGATOR_5707]. You may perform none, some, or all of these activities.  For each one on the 
list, please tell me whether you perform it on a routine basis. (Interviewer: Hand   Not at all 
 A little Some Quite a bit Very much so Extremely so 
__ Burning/stinging in 
eyes (     ) (     ) (     ) (     ) (     ) (     ) 
__ Redness in eyes (     ) (     ) (     ) (     ) (     ) (     ) 
__ Blurred vision (     ) (     ) (     ) (     ) (     ) (     ) 
__ Bitter taste (     ) (     ) (     ) (     ) (     ) (     ) 
__ Unusual taste (     ) (     ) (     ) (     ) (     ) (     ) 
__ Itchy eyes (     ) (     ) (     ) (     ) (     ) (     ) 
__ Discharge from eyes (     ) (     ) (     ) (     ) (     ) (     ) 
__ Swelling of eyelids (     ) (     ) (     ) (     ) (     ) (     ) 
__ Brow ache (     ) (     ) (     ) (     ) (     ) (     ) 
__ Dimming of vision    (     ) (     ) (     ) (     ) (     ) (     ) 
__ Difficulty in focusing 
from near to far (     ) (     ) (     ) (     ) (     ) (     ) 
__ Dry eyes (     ) (     ) (     ) (     ) (     ) (     ) 
__ Trouble reading (     ) (     ) (     ) (     ) (     ) (     ) 
__ Trouble seeing at 
night (     ) (     ) (     ) (     ) (     ) (     ) 
__ Tearing (     ) (     ) (     ) (     ) (     ) (     ) 
The PREPARE Study (V1)  
February, [ADDRESS_1020309] B ) 
 
__ Driving during the day 
__ Driving at night 
__ Lifting or carrying groceries 
__ Climbing 1 flight of stairs 
__ Walking several blocks 
__ Reading the newspaper 
__ Reading other than the newspaper 
 
 
8.  (Interviewer:)   I am now going to repeat each of the activities you just said you do 
routinely.  For each one, please tell me if you were limited at all in performi ng each 
activity in the past month because of the Treatment A regimen  (fewer-drops regimen 
administered by [CONTACT_099] & patient).  That is, were you limited:  not at all, a little, 
some, quite a bit, very much so, or extremely so? (Interviewer: Please check off under 
appropriate column below)  
 
 
 
9.  If you were limited in performing any activities due to the Treatment A regimen  
(fewer-drops physician & patient administered regimen) , during the past month, has 
your quality of life been interfered with by [CONTACT_746051]: not at  all, a little, 
some, quite a bit, very much so, or extremely so? 
 
__ Not at all 
__ A little 
__ Some 
__ Quite a bit  
__ Very much so  
__ Extremely so  
 
 
 
   Not at all 
 A little Some Quite a bit Very much so Extremely so 
__ Driving during day (     ) (     ) (     ) (     ) (     ) (     ) 
__ Driving at night (     ) (     ) (     ) (     ) (     ) (     ) 
__ Lifting or carrying 
groceries (     ) (     ) (     ) (     ) (     ) (     ) 
__ Climbing 1 flight of stairs (     ) (     ) (     ) (     ) (     ) (     ) 
__ Walking several blocks (     ) (     ) (     ) (     ) (     ) (     ) 
__ Reading the newspaper (     ) (     ) (     ) (     ) (     ) (     ) 
__ Reading other than the 
newspaper (     ) (     ) (     ) (     ) (     ) (     ) 
The PREPARE Study (V1)  
February, 2021  Page 45 
 CONFIDENTIAL  
Total Topi[INVESTIGATOR_746036]-administered: Patient Reporte d Outcomes 
 
10. (Interviewer: Read the following).  I am going to read to you a list of various side effects 
that may occur in some patients who receive Treatment B  (self-administered total 
eyedrop therapy following ophthalmic surgery) .  You may have experienced none, 
some, or all these side effects during the past month. As I read the list, pleas e tell me if 
you experienced that side effect. (Interviewer: Circle affirmative responses on the list 
below. Place a check under the column marked ‚ÄúI did not have the symptom‚Äù below for 
those symptoms not experienced by [CONTACT_102]. If patient expe rienced none of these 
side effects, please check "None of these symptoms" below and go to Q uestion # 10).  
 
11.  (Interviewer: Refer to Question #7 and read the following).  I am now going to read to 
you the side-effects you said you experienced in the last question.  For each side effe ct I 
mention, please tell me how frequently you experienced each side effect dur ing the past 
month. (interviewer- hand respondent Card "A" with frequency scales.)  That is, did 
you experience the side effect rarely, a few times, often, usually, almost always , or 
always? (Interviewer:  Place check under appropriate column below for each c ircled 
side effect mentioned by [CONTACT_225129]).  
 
 
   I Did Not 
Have the 
Symptom 
 Rarely A Few 
Times Fairly 
Often Usually Almost 
Always Always 
__ Burning/stinging in 
eyes (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Redness in eyes (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Blurred vision (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Bitter taste (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Unusual taste (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Itchy eyes (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Discharge from eyes (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Swelling of eyelids (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Brow ache (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Dimming of vision    (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Difficulty in focusing 
from near to far (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Dry eyes (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Trouble reading (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Trouble seeing at 
night (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ Tearing (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
__ None of these 
symptoms (     ) (     ) (     ) (     ) (     ) (     ) (     ) 
The PREPARE Study (V1)  
February, 2021  Page 46 
 CONFIDENTIAL  
 
 
 
12. (Interviewer: Refer to Question #7 and read the following).  I am again going to repeat 
the side-effects you just mentioned. For each side effect I mention, please t ell me if you have 
been bothered by [CONTACT_13114]: not at all, a little, some, quite a bit, very much so, or extremely s o? 
(Interviewer: Place check under appropriate columns below)  
 
 
 
13. During the past month has your quality of life been interfered with by [CONTACT_746050]:  
not at all, a little, some, quite a bit, very much so, or extremely so? 
 
__ Not at all 
__ A little 
__ Some 
__ Quite a bit 
__ Very much so 
__ Extremely so 
 
 
 
 
   Not at all 
 A little Some Quite a bit Very much so Extremely so 
__ Burning/stinging in 
eyes (     ) (     ) (     ) (     ) (     ) (     ) 
__ Redness in eyes (     ) (     ) (     ) (     ) (     ) (     ) 
__ Blurred vision (     ) (     ) (     ) (     ) (     ) (     ) 
__ Bitter taste (     ) (     ) (     ) (     ) (     ) (     ) 
__ Unusual taste (     ) (     ) (     ) (     ) (     ) (     ) 
__ Itchy eyes (     ) (     ) (     ) (     ) (     ) (     ) 
__ Discharge from eyes (     ) (     ) (     ) (     ) (     ) (     ) 
__ Swelling of eyelids (     ) (     ) (     ) (     ) (     ) (     ) 
__ Brow ache (     ) (     ) (     ) (     ) (     ) (     ) 
__ Dimming of vision    (     ) (     ) (     ) (     ) (     ) (     ) 
__ Difficulty in focusing 
from near to far (     ) (     ) (     ) (     ) (     ) (     ) 
__ Dry eyes (     ) (     ) (     ) (     ) (     ) (     ) 
__ Trouble reading (     ) (     ) (     ) (     ) (     ) (     ) 
__ Trouble seeing at 
night (     ) (     ) (     ) (     ) (     ) (     ) 
__ Tearing (     ) (     ) (     ) (     ) (     ) (     ) 
The PREPARE Study (V1)  
February, 2021  Page 47 
 CONFIDENTIAL  
 
 
 
 
 
14. (Interviewer ).  I am now going to show you  a list of activities you  might do during a 
typi[INVESTIGATOR_5707]. You may perform none, some, or all of these activities.  For each one on the 
list, please tell me whether you perform it on a routine basis. (Interviewer: Hand 
respondent Card B with activities and check each activity below that is  me ntioned  by  
[CONTACT_225129].  Then circle those activities for each patient on Card B ) 
 
__ Driving during the day 
__ Driving at night 
__ Lifting or carrying groceries 
__ Climbing 1 flight of stairs 
__ Walking several blocks 
__ Reading the newspaper 
__ Reading other than the newspaper 
 
 
15. (Interviewer:)   I am now going to repeat each of the activities you just said you do 
routinely.  For each one, please tell me if you were limited at all in performi ng each 
activity in the past month because of Treatment B (total topi[INVESTIGATOR_746037]).  That is, were you limited:  not at all, a little, some, quite a bit, very much 
so, or extremely so? (Interviewer: Please check off under appropriate column below)  
 
 
 
 
16. If you were limited in performing any activities due to Treatment B (total topi[INVESTIGATOR_746038]),  during the past month, has your quality of life been 
interfered with by [CONTACT_746051]: not at all, a little, some, qui te a bit, very 
much so, or extremely so? 
 
__ Not at all   Not at all 
 A little Some Quite a bit Very much so Extremely so 
__ Driving during day (     ) (     ) (     ) (     ) (     ) (     ) 
__ Driving at night (     ) (     ) (     ) (     ) (     ) (     ) 
__ Lifting or carrying 
groceries (     ) (     ) (     ) (     ) (     ) (     ) 
__ Climbing 1 flight of stairs (     ) (     ) (     ) (     ) (     ) (     ) 
__ Walking several blocks (     ) (     ) (     ) (     ) (     ) (     ) 
__ Reading the newspaper (     ) (     ) (     ) (     ) (     ) (     ) 
__ Reading other than the 
newspaper (     ) (     ) (     ) (     ) (     ) (     ) 
The PREPARE Study (V1)  
February, [ADDRESS_1020310] month, how often did you miss one or more doses of the eyedrop 
medication ? 
 
__ I did not miss any doses 
__ Rarely  
__ A few times 
__ Fairly often 
__ Usually 
__ Almost always  
__ Always 
 
 
 
 
 
18. Overall, how satisfied, if at all, have you been with the regimen you stated you 
preferred ? (Interviewer: Hand respondent Card C with satisfaction scales)  Would you 
say you were totally satisfied, very satisfied, somewhat satisfied, somewhat dis satisfied, 
very dissatisfied or totally dissatisfied ? (Interviewer: Record only one response below) 
 
__ Totally satisfied 
__ Very satisfied 
__ Somewhat satisfied 
__ Somewhat dissatisfied 
__ Very dissatisfied 
__ Totally dissatisfied 
 
 
Thank respondent and terminate interview. 
 
 
Signature [CONTACT_746053] (V1)  
February, [ADDRESS_1020311] C 
 
Totally satisfied 
 
Very satisfied 
 
Somewhat satisfied 
 
Somewhat dissatisfied 
 
Very dissatisfied 
 
Totally dissatisfied 
 
 